INTRODUCTION
Recent application of malaria control strategies has succeeded in reducing the malaria burden in endemic regions [1] [2] [3] [4] [5] , yet malarial anemia remains a major cause of morbidity and mortality [6, 7] . Plasmodium falciparum malaria in Kenyan children was reported to account for up to 75% of anemia-associated deaths and 9% of all deaths [7] . Furthermore, children with severe malarial anemia had a mortality rate of 8.6%, compared with 3.6% in children with severe anemia due to other causes [7] .
Malarial anemia is well known as a major complication of symptomatic parasitemia. Less well known is that it is also significantly associated with low-density asymptomatic parasitemia in children [8, 9] . This, coupled with the fact that a large proportion (dependant on factors such as population age, natural immunity, and transmission rate) of infections in endemic areas are asymptomatic [10] [11] [12] [13] [14] , means that the potential to further reduce the burden of malarial anemia through the treatment of asymptomatic carriers is promising.
It is already known that interventions that reduce malaria transmission, such as insecticide-treated nets and chemoprophylaxis, can improve hemoglobin (Hb) levels in children [15] [16] [17] , and that treatment of asymptomatic children can improve their cognitive ability, possibly as a result of raised Hb levels [18] . 
MATERIALS AND METHODS
Full study methodology has previously been published by Tiono et al. [19] .
Study Design
This was a single-center, controlled, parallel, cluster-randomized study that evaluated the effect of systematic treatment of P. falciparum asymptomatic carriers at a community level on Hb levels and anemic status of children (\5 years) and adults over a 12-month period, compared with no treatment of asymptomatic carriers. The study was carried out between November 2010 and February 2012. Clusters were randomized and assigned in a 1:1 ratio to the control or intervention arm.
During the implementation phase of the study, intervention and control village inhabitants participated in Campaigns 1-3 that took place approximately 1 month apart, before the start of the rainy season. Campaign 4 was conducted after the rainy season had ended to mark the end of the study at 12 months ( Fig. 1) [19] . At each campaign, finger-prick blood samples were taken from the entire study population in the intervention arm and a randomly selected 40% in the control arm for screening for P. falciparum asexual forms and gametocytes, and assessment of Hb level (only performed during Campaigns 1 and 4). In the intervention arm, the population was screened using RDT ( were not screened by RDT-microscopy alone with delayed reading was used to ensure that study personnel and screened subjects remained unaware of a subject's status.
Study Population
The study took place in the health district of Saponé, about 50 km south of Ouagadougou in Burkina Faso, an area with marked seasonal (June to November) P. falciparum malaria transmission [22] . Eighteen clusters, each comprising of one village, were selected for inclusion in the trial. All inhabitants of each cluster were invited to participate in the trial.
Written informed consent was received from all study participants or their legal guardians.
Interventions
All members of the study population who were 
Monitoring
Throughout the study, community healthcare workers visited households to check and document treatment adherence of asymptomatic carriers and those with symptomatic malaria through the use of a drug accountability log and tablet counts. The use of LLINs was checked at the home visits conducted at least every two months, and additional training was provided when required. Adverse events and serious adverse events were also recorded, as previously described by Tiono et al. [19] .
Study Medication
All individuals with a positive RDT in the intervention arm received AL/AL dispersible given. Full details have previously been published by Tiono et al. [19] .
Laboratory Methods
Hb level was measured using the HemoCue 
Statistical Analysis
Data analysis, performed with SAS Ò Software (Version 9.3; SAS Institute, Cary, NC, USA) of the SAS System for Unix, followed a cluster-level 
Outcome Measures and Endpoints
In order to quantify a potential direct benefit on Hb levels associated with AL treatment in asymptomatic carriers, outcomes were assessed in subjects with microscopy-confirmed asymptomatic malaria detected on Day 1 of Campaign 1. Separate outcomes aimed at assessing the potential improvement of community-wide Hb levels were also conducted.
Outcomes in Microscopy-Confirmed Asymptomatic Carriers
The first primary endpoint was the number of RDT and microscopy-confirmed cases of symptomatic malaria with a parasite density 
RESULTS
A total of 6,817 persons in the intervention arm and 7,258 persons in the control arm were enrolled, and 86.5% (5,897) of the persons in the intervention arm and 89.7% (6,510) of the persons in the control arm completed the study (Fig. 2) . Larger increases in Hb were seen in the intervention arm relative to the control arm in subjects with medium and high baseline parasite densities as compared with those with low densities (Fig. 3) . A more substantial improvement in the proportion of asymptomatic carriers aged [6 months to \5 years with anemia (mild, moderate or severe) was seen in the intervention arm than in the control arm over the first 28 days (Day 1 to Day 28 of Campaign 1). The proportion of asymptomatic carriers with anemia in the intervention arm decreased by 31.1% (from 75.7% to 44.6%), compared with a decrease of 4.7% (from 76.3% to 71.6%) in the control arm (Fig. 4) . (from 75.7% to 45.8%), compared with a decrease of 36.8% (from 76.3% to 39.5%) in the control arm (Fig. 4) . However, there was no marked difference in the reduction of The difference between the increase in Hb from Campaign 1 to 4 in subjects aged 5-9, 10-14, and C15 years in the two arms was not 
DISCUSSION
In this study, community screening and targeted treatment of asymptomatic carriers of P. falciparum malaria had a significant impact on short-term (28 days) Hb levels in these asymptomatic carriers, including significantly improving Hb levels in all asymptomatic carriers [6 months, and reducing the incidence of anemia in asymptomatic carriers aged [6 months to \5 years by over 30%.
However, more research is needed to understand if this is a direct effect of AL therapy. While it is known that AL has a consistently high efficacy and safety in the treatment of P. falciparum malaria [20] , some factors in this study, such as the concurrent treatment of all symptomatic cases in both arms, and the use of LLINs, may have contributed to the improved Hb levels. It should be noted that these short-term improvements in Hb levels did correlate with the reduction in carriage of asexual forms and gametocytes seen in these asymptomatic carriers after 28 days of AL therapy (there was a significant reduction in asymptomatic and gametocyte carriage from baseline to the assessment at the beginning of Campaigns 2 and 3) [19] . Only 0.2% of patients in the While the interventions in the study resulted in a significantly greater increase in Hb in asymptomatic carriers aged [6 months over 28 days in the intervention arm than in the control arm, this improvement was not of a sufficient magnitude to be considered clinically meaningful. This was probably because the mean baseline Hb level in both arms was within the normal range (intervention:
11.81 g/dl; control 11.86 g/dl), making a large increase in Hb unlikely. However, over these 28 days, it is encouraging that (a) a significantly larger proportion of asymptomatic carriers aged [6 months up to \5 years in the intervention arm raised their Hb levels by C2.0 g/dl than in the control arm (Fig. 2) , and (b) the proportion of these asymptomatic carriers with anemia in the intervention arm decreased substantially more than that in the control arm (31.1% vs.
4.7%; Fig. 4).
It is interesting to note that while the reduction in anemia in asymptomatic carriers was sustained in the intervention arm over 12 months, anemia was also reduced in the control arm over this period. This suggests a possible study effect owing to the availability of AL for all confirmed cases of symptomatic malaria and the provision of an LLIN to every participant in the study. A recent study, which examined the coverage of malaria control interventions in Burkina Faso, reported that 59% of households in the study population owned an insecticide-treated bednet (ITN) and only 34% of children under 5 years of age with a reported malaria case were treated with an artemisinin-based combination therapy (ACT) [23] . It is, therefore, possible that receipt of an LLIN by every study participant increased the use of ITNs in both study arms. A Cochrane Review of the impact of medicated bednets concluded that sleeping under one improved Hb level in children by 1.7% packed cell volume [24] . Additionally, the high level of general medical attention and easy availability of a high-quality ACT to treat confirmed malaria cases throughout the duration of the study may have contributed to a reduction in parasite levels in both arms as compared with baseline [19] .
While the impact of improved Hb levels on quality of life is not known, it has previously been shown that asymptomatic infection can also affect cognitive performance, and that treatment of asymptomatic malaria improves children's cognitive ability [18] . It has also been shown, through fixed effects estimates, that asymptomatic malaria and the presence of P. falciparum malaria parasites have a direct, causal correlation with educational achievement and cognitive performance in primary school children [25] . Further research is needed to understand the potential benefit on quality of life of improving Hb levels through treatment of asymptomatic carriers with AL. This is particularly pertinent as asymptomatic carriers tend not to seek treatment yet may benefit from AL therapy.
Hb levels in the community (all subjects) increased over 12 months, with no significant difference between the intervention and control arms in mean levels or distribution, and median and 25th percentile Hb levels remained above the defined limit for anemia at all times in both arms. Again, the treatment of all symptomatic cases, and the widespread use of LLINs in both arms, could make it difficult to identify any direct benefit on Hb levels due to the treatment of asymptomatic carriers in the intervention arm.
CONCLUSION
This study demonstrates that systematic screening and treatment of asymptomatic carriers of P. falciparum with AL at the community level may improve Hb levels and reduce the prevalence of anemia in asymptomatic children over the short term. 
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